21st Austria weekly - Marinomed (11/09/2024)

Marinomed: Marinomed Biotech AG has received the certificates for the first two Carragelose products under the new medical device regulation (MDR). According to the company, two Carragelose nasal sprays have received declaration of conformity under the new medical device regulation, certificates for further products are expected later in the year. Eva Prieschl-Grassauer, CSO of Marinomed, comments: “MDR-transition and the associated necessary documentation is very demanding. However, thanks to the excellent work of our regulatory affairs team and the extensive clinical data that we have generated for Carragelose over the years, we are able to meet the new requirements. The issuing of these certificates is further confirmation of the quality, safety and appropriate technical documentation of our Carragelose products and increases the value of this asset, also for a potential strategic partner. We are proud to have received the first certificates well before the end of the transition period in 2028. We are confident that the other products will also be certified under the new MDR and will therefore continue to be approved for marketing and distribution in the EU.”
Marinomed Biotech: weekly performance: 81.48%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (11/09/2024)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #759: ATX Murmeltiermodus, Frequentis lädt Private zum CEO-Talk und A Message to you Rudi Fußi

Bildnachweis

1. 21st Austria Weekly

Aktien auf dem Radar:Porr, voestalpine, Addiko Bank, Austriacard Holdings AG, CA Immo, Amag, VIG, Erste Group, Verbund, SBO, Wienerberger, Andritz, Polytec Group, Cleen Energy, EuroTeleSites AG, Flughafen Wien, Josef Manner & Comp. AG, Marinomed Biotech, Pierer Mobility, Stadlauer Malzfabrik AG, Agrana, EVN, Österreichische Post, S Immo, Telekom Austria, Uniqa, Warimpex.

Random Partner

---

Evotec
Evotec ist ein Wirkstoffforschungs- und -entwicklungsunternehmen, das in Forschungsallianzen und Entwicklungspartnerschaften mit Pharma- und Biotechnologieunternehmen, akademischen Einrichtungen, Patientenorganisationen und Risikokapitalgesellschaften Ansätze zur Entwicklung neuer pharmazeutischer Produkte vorantreibt.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner